Skip to main content
. 2016 Nov 2;7(51):84508–84519. doi: 10.18632/oncotarget.13022

Figure 5. Anti-miR-21, anti-miR-155, or combined anti-miR-21 and anti-miR-155 treatment inhibits lung cancer cell growth in vitro and in vivo.

Figure 5

(A) The apoptosis rates of A549 and H1299 cells treated with 100 nM miR-NC, miR-21, miR-155, or miR-21/155 antisense for 24 hours. (B) The proliferation rates of A549 and H1299 cells treated with 100 nM miR-NC, miR-21, miR-155, or miR-21/155 antisense at different time points, as analyzed by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay.*p < 0.05, **p < 0.01. (C–D) Colony formation assay of A549 (C) and H1299 (D) cells treated with 100 nM miR-NC, miR-21, miR-155, or miR-21/155 antisense. Colony numbers were counted after 10 days.*p < 0.05, **p < 0.01. (E) Tumor growth rate in mice injected with A549 cells transfected with miR-NC, miR-21, miR-155, or miR-21/155 antagomirs. (F) The tumor image of (E) analyzed with a nuclear magnetic resonance (MRI) assay. (G) Immunohistochemical analysis of the protein levels of SOCS1, SOCS6, and PTEN in tumor samples derived from mice implanted with A549 cells pre-treated with miR-NC, miR-21, miR-155, or miR-21/155 antagomirs.